Clinical features and hyperplastic patterns of parathyroid glands in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxacalcitol treatment and required parathyroidectomy

Therapeutic Apheresis and Dialysis

Volumn 11, Issue 4, 2007, Pages 266-273

  Tominaga, Yoshihiro ^a   Matsuoka, Susumu ^a   Sato, Tetsuhiko ^a   Uno, Nobuyuki ^a   Goto, Norihiko ^a   Katayama, Akio ^a   Haba, Toshihito ^a   Uchida, Kazuharu ^a  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

Maxacalcitol; Parathyroid hyperplasia; Parathyroidectomy; Secondary hyperparathyroidism

Indexed keywords

22 OXACALCITRIOL; CALCIUM; PHOSPHATE;

ADULT; ARTICLE; CLINICAL FEATURE; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; ORGAN WEIGHT; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PATIENT ASSESSMENT; PRIORITY JOURNAL; SAMPLE SIZE; SECONDARY HYPERPARATHYROIDISM;

AGED; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; COMBINED MODALITY THERAPY; COMORBIDITY; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPLASIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; ORGAN SIZE; PARATHYROID GLANDS; PARATHYROIDECTOMY; RENAL DIALYSIS;

EID: 34547195157     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2007.00489.x     Document Type: Article

References (24)

1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis patients. J Am Soc Nephrol 2004 15 : 2208 18.
2. Slatopolsky E, Dusso A, Brown AJ. Control of uremic bone disease: role of vitamin D analogs. Kidney Int 2002 61 : S143 8.
3. Murayama E, Miyamoto K, Kubodera N et al. Synthetic studies of vitamin D3 analogues. VIII. Synthesis of 22-oxavitamin D3 analogues. Chem Pharm Bull (Tokyo) 1986 34 : 4410 13.
4. Hirata M, Endo K, Ohkawa H et al. A comparison between 1,25-dihydroxy-22-oxavitamin D3 and 1,25-dihydroxyvitamin D3 regarding suppression of parathyroid hormone secretion and calcaemic action. Nephrol Dial Transplant 2002 17 (Suppl 10 S41 5.
5. Koike N, Hayakawa N, Tokuda K, Nishimiya K, Saito K, Stumpf WE. In vivo time-course of receptor binding in the parathyroid gland of the vitamin D analogue (3H) 1,25-dihydroxy-22-oxavitamin D3 compared with (3H) 1,25-dihydroxyvitamin D3, determined by micro-autoradiography. Nephrol Dial Transplant 2002 17 (Suppl 10 S53 7.
6. Akizawa T, Suzuki M, Akiba T et al. Long-term effect of 1,25-dihydroxy-22oxavitamin D3 on secondary hyperparathyroidism in haemodialysis patients. One-year administration study. Nephrol Dial Transplant 2002 17 (Suppl 10 S28 36.
7. Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Kurokawa K. Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients. Am J Kidney Dis 2001 38 (Suppl 1 S147 51.
8. Doi S, Yorioka N, Usui K, Shigemoto K, Harada S. Effect of 22-oxacalcitriol on secondary hyperparathyroidism in hemodialysis patients. Intern Med 2003 42 : 955 9.
9. Tominaga Y, Sato K, Numano M, Uchida K, Takagi H. Histopathology and pathophysiology of secondary hyperparathyroidism due to chronic renal failure. Clin Nephrol 1995 1 : S42 7.
10. Tominaga Y, Tanaka Y, Sato K et al. Histopathology, pathophysiology and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997 13 : 78 86.
11. Tominaga Y, Kohara S, Namii Y et al. Clonal analysis of nodular parathyroid hyperplasia gland in renal hyperparathyroidism. World J Surg 1993 20 : 744 50.
12. Tominaga Y, Tsuzuki T, Uchida K et al. Expression of PRAD1/cyclinD1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 1999 55 : 1375 83.
13. Fukuda N, Tanaka H, Tominaga Y et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993 92 : 1436 43.
14. Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997 51 : 328 36.
15. Tominaga Y, Inaguma D, Matsuoka S et al. Is the volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial 2006 10 : 198 204.
16. Giangrande A, Castiglione A, Solbiasti L, Allaria P. Ultrasound guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Nephrol Dial Transplant 1992 7 : 412 21.
17. Tominaga Y, Numano M, Tanaka Y, Uchida K, Takagi H. Surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997 13 : 87 96.
18. Tominaga Y, Matsuoka S, Sato T. Surgical indications and procedures of parathyroidectomy in patients with chronic kidney disease. Ther Apher Dial 2005 9 : 44 7.
19. Tominaga Y, Numano M, Uchida K et al. Parathyroidectomy for patients with renal hyperparathyroidism refractory to calcitriol pulse therapy. J Bone Miner Metab 1994 12 (Suppl 1 S99 104.
20. Fukagawa M, Kitaoka M, Yi H et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 1994 68 : 221 8.
21. Douthat WD, Orozco SE, Arteaga JD, Massari PU. Treatment of refractory secondary hyperparathyroidism with ethanol injection: the importance of gland volume. Kidney Int 2003 63 (Suppl 85 S101 4.
22. Katoh N, Nakayama M, Shigematsu T et al. Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism. Am J Kidney Dis 2000 35 : 465 8.
23. Okuno S, Ishimure E, Kitatani K et al. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2003 18 : 2613 21.
24. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 (Suppl 42 S1 202.